BOULDER, Colo., Jan. 10, 2019 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma (CTCL) and in adult […]Continue Reading ...
In recent years, an overwhelming body of clinical evidence has firmly established the HIV Undetectable = Untransmittable (U=U) concept as scientifically sound, say officials from the National Institutes of Health. U=U means that people living with HIV who achieve and maintain an undetectable viral load–the amount of HIV in the blood–by taking and adhering to […]Continue Reading ...
As a research scientist, I’ve negotiated the complex nature of getting approval to image human subjects. So I know firsthand that it is common to exclude pregnant women from clinical trials. Although this practice is well-intentioned, it is also misguided — according to an opinion piece recently published in JAMA. To learn more, I spoke […]Continue Reading ...
The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc., announce that the FDA has approved the initiation of a first-in-human clinical trial investigating the safety and tolerability of a novel synthetic DNA-encoded monoclonal antibody (DMAb) therapeutic technology for the prevention of Zika virus infection. DMAb therapeutic technology is unlike all known conventional […]Continue Reading ...
LAVAL, QUEBEC, CANADA, – December 5, 2018 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or the “Corporation”) today confirmed its decision to formally pursue Alström syndrome (AS) as a clinical indication for PBI-4050 following positive feedback from its recent meetings with regulatory authorities. These meetings have provided Prometic with clear clinical and […]Continue Reading ...
Gemcitabine given in combination with nab-paclitaxel is the standard of care for patients with advanced pancreatic cancer. This practice, however, rests on data obtained from several recent clinical trials enrolling patients with pancreatic cancer who skewed younger and in better overall condition than most. Currently, there is limited data regarding the management of patients who […]Continue Reading ...
BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) — miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of cobomarsen, an inhibitor of miR-155, in mycosis fungoides (MF) […]Continue Reading ...
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The […]Continue Reading ...
Jan 11 2019 First of its kind, ‘on demand’ supply service for clinical trials to be offered Clinigen Group plc (‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Trial Service (‘CTS’) business has extended its exclusive European clinical trial supply agreement with Accord Healthcare (‘Accord’). Clinigen is also offering pharma companies an […]Continue Reading ...
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal […]Continue Reading ...
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 3, 2019– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared an update on clinical trial sites in the United States and recent international clinical trial application approvals to perform the Phase 3 PolarisDMD trial for edasalonexent (CAT-1004) in Duchenne muscular dystrophy (DMD). PolarisDMD clinical trial sites in the United States […]Continue Reading ...
Columbia’s Celiac Disease Center will take part in a clinical trial to test what could be the first vaccine for people with the autoimmune disease.Continue Reading ...
Breda, the Netherlands / Ghent, Belgium – December 03, 2018 — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) […]Continue Reading ...
GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the pivotal Phase 3 clinical trial, the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Anders Rabbe, chief executive officer of Isofol, said, “We look forward to bringing arfolitixorin to all patients […]Continue Reading ...
San Mateo, Calif, Nov 14, 2018 – Attenua, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced that the first patient has been treated in a Phase 2 clinical trial in chronic cough with bradanicline (formerly known as ATA-101), its lead compound. “Within just six months of our initial […]Continue Reading ...
- B-group vitamins may be beneficial for people with first episode psychosis
- Researchers demonstrate how manganese produces parkinsonian syndrome
- Researchers suggest link between personality type and attitude towards others’ bodies
- Mutant mice administered with cocaine failed to exhibit hyperactivity, shows study
- Health Tip: Understanding a Heart Murmur
- Gut protein mutations shield against spikes in glucose
- Engineered immune cells target broad range of pediatric solid tumors in mice | News Center
- Study finds link between high pesticide exposure and poor sense of smell among farmers
- New study finds only 13% of outpatient antibiotic prescriptions to be appropriate
- New project receives €8.65 million from EU and Canada to ease genomic, health data sharing
- Improvements in pharmacological study to fight cognitive impairment in schizophrenia
- Study looks at trends over time in oral antibiotic prescribing by dermatologists
- Most substance use disorder treatment facilities do not offer medication treatment
- Multiple sclerosis could benefit from stem cell therapy
- Researchers manipulate T cells to improve transplant success
- Put away your rulers and reach for your phone
- Integrated care to women with PMADs offered at several levels
- Researchers identify MANF as a rejuvenating factor in parabiosis
- Truncal mutations study suggests new direction in origins of cancer
- Beckman Coulter launches new ClearLLab 10C System for clinical flow cytometry lab